Neurocrine Biosciences, Inc. (NBIX)
NBIXNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$168.05
-0.8100 (-0.48%) today
Regular session, Nov 10, 2:59 PM ET
- Market cap
- $17.03bn
- P/E
- 21.1
- EPS, last 4 quarters
- $7.98
- Dividend yield
- –
- Day range
- $166.75 to $169.42
- 52-week range
- $122.14 to $186.12
- Average volume
- 1.35m
- Previous close
- $168.86
Analysts
20 coveringBuy17 buy, 3 hold, 0 sell
Targets a year out average $206.42, +22.8% from here
Earnings
next estimate $2.13Next report
Dec 2025
-19.7%
Mar 2026
+10.2%
Jun 2026
+25.5%
Sep 2026
+42.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $805.50m | $814.50m | $959.00m | $1.12bn |
| Gross profit | $784.90m | $800.70m | $935.90m | $1.10bn |
| Operating income | $210.90m | $193.40m | $151.50m | $331.30m |
| Net income | $153.70m | $197.90m | $144.40m | $206.50m |
Last four quarters: revenue $3.70bn, margin 19.0%, free cash flow $1.04bn
News
8 latest- Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice Zacks · 1 day ago
- All You Need to Know About Neurocrine (NBIX) Rating Upgrade to BuyZacks · 1 day ago
- NBIX vs. GRDN: Which Stock Is the Better Value Option?Zacks · 1 day ago
- Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?Zacks · 1 day ago
- Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13% RTTNews · 7 days ago
- NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales ViewZacks · Nov 3, 2026
- Neurocrine (NBIX) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 2, 2026
- Neurocrine Biosciences Q3 Earnings Call HighlightsMarketBeat · Nov 2, 2026
The company
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis*, and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- neurocrine.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.